Oral curcumin (meriva) is effective as an adjuvant treatment and is able to reduce IL-22 serum levels in patients with psoriasis vulgaris by Antiga, Emiliano et al.
Clinical Study
Oral Curcumin (Meriva) Is Effective as an Adjuvant
Treatment and Is Able to Reduce IL-22 Serum Levels in Patients
with Psoriasis Vulgaris
Emiliano Antiga, Veronica Bonciolini, Walter Volpi, Elena Del Bianco, and Marzia Caproni
Section of Dermatology, Department of Surgery and Translational Medicine, University of Florence, Viale Michelangiolo 41,
50125 Florence, Italy
Correspondence should be addressed to Emiliano Antiga; emiliano.antiga@unifi.it
Received 16 March 2015; Accepted 5 May 2015
Academic Editor: Oscar Palomares
Copyright © 2015 Emiliano Antiga et al.This is an open access article distributed under theCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Curcumin is a complementary therapy that may be helpful for the treatment of psoriasis due to its anti-inflammatory,
antiangiogenic, antioxidant, and antiproliferative effects. In the present study we performed a randomized, double-blind, placebo-
controlled clinical trial to assess the effectiveness of a bioavailable oral curcumin in the treatment of psoriasis. Sixty-three patients
with mild-to-moderate psoriasis vulgaris (PASI < 10) were randomly divided into two groups treated with topical steroids and
Meriva, a commercially available lecithin based delivery system of curcumin, at 2 g per day (arm 1), or with topical steroids alone
(arm 2), both for 12 weeks. At the beginning (T0) and at the end of the therapy (T12), clinical assessment and immunoenzymatic
analysis of the serum levels of IL-17 and IL-22 were performed. At T12, both groups achieved a significant reduction of PASI values
that, however, was higher in patients treated with both topical steroids and oral curcumin than in patients treated only with topical
steroids. Moreover, IL-22 serum levels were significantly reduced in patients treated with oral curcumin. In conclusion, curcumin
was demonstrated to be effective as an adjuvant therapy for the treatment of psoriasis vulgaris and to significantly reduce serum
levels of IL-22.
1. Introduction
Psoriasis is a common chronic inflammatory disease of the
skin, nails, and joints, which affects about 2% of the general
population [1], with a significant impact on long-term quality
of life [2].The potential organ toxicity associated with chron-
ically used systemic drugs, their immunosuppressive effects
with the increased risk of infections and malignancies, and
the high costs of some of them justify a novel assessment of
therapeutic targets and modalities in patients with psoriasis
[3, 4].
An estimated 80% of individuals in developing coun-
tries depend primarily on natural products to meet their
healthcare needs, and recent surveys suggest that one in
three Americans also uses medicinal natural products daily
[5]. With regard to psoriasis, 51% of the patients use com-
plementary and alternative medicine therapies to treat their
skin, despite limited or no scientific data on the safety
and efficacy of these treatments [6]. Among them, cur-
cumin (dihydroferuloyl-methane, the active component of
the Indian spice turmeric) has been used for centuries in
traditional medicines of China and India [7], paving the way
for the development of several studies both in cultured cells
and in animal models, which revealed a surprisingly wide
range of beneficial properties of this yellow-pigmented spice,
including anticancer and anti-inflammatory activity [8–12].
Furthermore, the extremely good safety profile of curcumin
represents the most compelling and key rationale for its use,
as to date no studies have discovered any relevant toxic effects
even at very high doses [13, 14]. Whereas curcumin has sev-
eral molecular targets, it may be promising for the treatment
of psoriasis interacting with the main pathogenetic pathways
of the disease, namely, T cell-mediated inflammation via
the inhibition of nuclear factor kappa B (NF-𝜅B) [15–17],
keratinocyte proliferation, inhibiting phosphorylase kinase
(PhK) [18–20], and angiogenesis [21–23].
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The use of curcumin in the treatment of psoriasis is
essentially based on anecdotal reports; however, few previous
studies investigated its efficacy in psoriasis patients. In partic-
ular, Heng et al. [24] tested the effect of topical curcumin in
10 patients with psoriasis. Interestingly, topical curcumin was
able to improve psoriasis lesions and to inhibit PhK activity,
supporting the hypothesis that effective antipsoriatic activity
may be achieved through the modulation of keratinocyte
proliferation. In another study [25], the oral formulation of
curcumin has been tested in patients with moderate to severe
psoriasis vulgaris, with a low overall response rate.
In this study, we usedMeriva, a novel bioavailable lecithin
based delivery form of curcumin [26] as an adjuvant therapy
for the treatment of patients with mild-to-moderate psoriasis
vulgaris. In particular, we compared the efficacy of topi-
cal methylprednisolone aceponate 0.1% plus oral curcumin
versus topical methylprednisolone aceponate 0.1% plus oral
matching placebo. Moreover, we investigated the effects of
such a treatment on the serum levels of IL-17 and IL-22 that
represent the prototypical cytokines secreted by T helper 17
(Th17) and T helper 22 (Th22) cells, respectively, and are
thought to play amajor role in the pathogenesis of the disease
[27–33].
2. Materials and Methods
2.1. Study Population. Patients having mild-to-moderate
plaque psoriasis histologically confirmed with a Psoriasis
Area Severity Index (PASI) < 10 were included into the
study. The exclusion criteria were the following: patients < 18
years old; patients with guttate, erythrodermic, or pustular
psoriasis, as well as with psoriatic arthritis; patients who
used systemic treatments for psoriasis within 3 months
before day 0 or at any time during the study; patients who
used topical treatments or phototherapy for psoriasis in the
month before the study or at any time during the study;
pregnant or lactating women, or women of childbearing age
not using a reliable method of contraception; patients with
clinically significant laboratory abnormalities at screening, or
significant uncontrolled comorbidities. Enrolled participants
were required to avoid prolonged exposure to sun orUV light
and to discontinue nonmedicated emollients and medicated
psoriasis shampoos 24 hours before each study visit. The
study was conducted in accordance with the Declaration of
Helsinki and was approved by the institutional review board
of the Hospital Ospedale Piero Palagi (Florence, Italy); all
patients gave written informed consent.
2.2. Study Product. Patients were instructed to take 2 tablets
2 times a day, each tablet containing 500mg Meriva (Indena
SpA, Milan), for an overall daily dose of 2 g.
Meriva is a patented delivery form of the dietary phenolic
curcumin, resorting to the use of lecithin (from non-GMO
sources) to boost the absorption and bioavailability. The two
ingredients form a noncovalent adduct in a 1 : 2 weight ratio,
and two parts of microcrystalline cellulose are then added to
improve flowability, with an overall content of curcumin of
20% (e.g., 100mg for each tablet).
2.3. Study Design. This was a phase III, single-dose, ran-
domized, double-blind, placebo-controlled clinical trial in
patients with chronic plaque psoriasis. The study was per-
formed at the Department of Surgery and Translational
Medicine, Section of Dermatology (University of Florence,
Italy), and consisted in a screening period, a baseline time
in which PASI score was assessed and the patients started
the treatment, a treatment period of 12 weeks, and a 4-week
follow-up period. Patients were randomly assigned in a 1 : 1
ratio to receive topical methylprednisolone aceponate 0.1%
ointment (once daily on the lesions) plus 2 g per day of
Meriva (2 tablets of 500mg, twice daily) (arm 1) or topical
methylprednisolone aceponate 0.1% ointment (once daily on
the lesions) plusmatching placebo (2 tablets identical for size,
form, and color from the verum, twice daily) (arm 2).
Patients were seen at a screening visit and then at baseline
(T0) and weeks 4, 8, 12 (T12), and 16 (T16) for safety and
efficacy evaluations. At T0 and at T12, serum samples were
collected to investigate the levels of IL-17 and IL-22. The
first participant was enrolled on May 3, 2012, and all study
procedures were concluded on May 27, 2014.
2.4. Efficacy Endpoints. The primary objective of the study
was to assess the superiority of topical methylprednisolone
aceponate plus Meriva (arm 1) over topical methylpred-
nisolone aceponate plus placebo (arm 2), evaluating the
reduction of disease activity calculated by PASI (a composite
evaluation instrument for psoriasis severity, with subscores
for erythema, induration, scaling, and percentage of body-
surface area affected) in both arms after 12 and 16 weeks
from baseline. Secondary efficacy endpoints included PASI
50, PASI 75, PASI 90, and PASI 100 (reductions of 50%, 75%,
90%, and 100%, resp., in the baseline PASI score) that have
been shown to represent a meaningful endpoint in psoriasis
clinical trials [34]. Each endpoint was assessed by means of a
between-group comparison of the proportion of patients who
met the criterion for that objective.
2.5. Safety Endpoints. All patients who received at least one
dose of study product were included in the safety analysis.
Safety datawere obtained by patient interview and the clinical
examination conducted by the physician at all study visits.
2.6. Cytokine Analysis. Blood samples were collected from
patients of both groups at baseline and T12 and were
centrifuged for 20min at 10,000×g (5417R microcentrifuge;
Eppendorf, Hamburg, Germany). Then, serum samples
were subdivided into small aliquots to be stored at −80∘C
until tested for cytokine levels. Solid-phase enzyme-linked
immunosorbent assay (ELISA) kits were used to determine
IL-17 and IL-22 serum levels (R&D Systems, Minneapolis,
MN, USA), according to the manufacturer’s instructions.
Results are expressed in picogram per milliliter (pg/mL) as
mean ± standard deviation. Samples and standards were
analyzed in duplicate and only variation coefficients <15%
were accepted.
2.7. Statistical Analysis. Statistical analysis of clinical efficacy
of curcumin was performed with aWilcoxon signed rank test
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Figure 1: Flowchart of participant enrollment.
between the pretreatment and posttreatment groups, and a
Wilcoxon rank sum test was used for comparing arm 1 with
arm 2. The serological data of IL-17 and IL-22 were analyzed
with Student’s 𝑡-test. In order to verify the homogeneity
of the two groups, we preliminarily compared clinical and
serological parameters between the two pretreated series.
Differences were considered as statistically significant when
𝑃 < 0.05.
3. Results
A total of 85 patients were screened, 63 of whom were
enrolled and were randomized in one of the two arms
(Figure 1). Of the 22 participants who were not included in
the study, 4 were excluded because they had a PASI > 10,
9 had used topical treatments within 30 days before day 0,
5 had used systemic treatments within 3 months before day
0, and 4 had concurrent arthropathy. Baseline demographic
information of the participants is reported in Table 1.
Thirty-one patients were randomized into arm 1, while
32 into were randomized arm 2. Of the 31 patients enrolled
into arm 1, 25 completed the trial up to week 16. Six out
of 31 enrolled participants into arm 1 did not complete the
trial. Two were withdrawn by the investigators before week 12
because of lack of efficacy and one for side effects (diarrhoea)
and 3 were lost to follow-up.
Of the 32 patients into arm 2, 24 completed the trial
up to week 16. Eight out of 32 enrolled participants did not
complete the trial. Six were withdrawn by the investigators
before week 12 because of lack of efficacy and/or worsening
of their psoriasis and two for side effects (papular eruption
on the face and nausea, resp.).
3.1. Efficacy Endpoints. Median PASI values [25th–75th per-
centile] at T0 were 5.6 [4.2–7.3] for arm 1 and 4.7 [3.8–5.8] for
arm 2. At T12, both groups achieved a significant reduction
Table 1: Baseline demographic information of the participants.
Arm 1 (𝑛 = 31) Arm 2 (𝑛 = 32)
Sex 14 M, 17 F 18 M, 14 F
Age (median, range) 37 (19–62) 41 (22–59)
Race 30 Caucasian1 Hispanic 32 Caucasian
Onset age (median, range) 31 (14–54) 35 (20–51)
of PASI values (arm 1: PASI at T12 = 1.3 [0.6–1.7], PASI T0
versus PASI T12: 𝑃 < 0.05; arm 2: PASI at T12 = 2.4 [1.4–
3.0], PASI T0 versus PASI T12: 𝑃 < 0.05; Figure 2). However,
the reduction of PASI values was higher in patients treated
with both topical steroids andMeriva (arm 1) than in patients
treated with topical steroids plus placebo (arm 2) (𝑃 < 0.05).
The reduction of PASI remained significant for both groups
at T16 (arm 1: PASI at T16 = 1.4 [1.2–1.8], PASI T0 versus
PASI T16: 𝑃 < 0.05; arm 2: PASI at T16 = 2.5 [1.8–3.3],
PASI T0 versus PASI T16: 𝑃 < 0.05; Figure 2). Moreover, at
T16, patients included in arm 1 still had a more significant
reduction in PASI values versus those included in arm 2 (𝑃 <
0.05; Figure 2).
Regarding the secondary efficacy endpoints, at T12, 23
patients in arm 1 (92%) and 13 in arm 2 (54%) achieved PASI
50, 12 patients in arm 1 (48%) and 3 in arm 2 (12%) achieved
PASI 75, 5 patients in arm 1 (20%) and 1 in arm 2 (4%)
achieved PASI 90, and 3 patients in arm 1 (12%) and 1 in arm
2 (4%) achieved PASI 100 (Table 2).
At the follow-up visit four weeks after the completion of
the therapy, at T16, 22 patients in arm 1 (88%) and 11 in arm
2 (46%) still maintained PASI 50, 11 patients in arm 1 (44%)
and 2 in arm 2 (8%) maintained PASI 75, 2 patients in arm 1
(8%) and none in arm 2 maintained PASI 90, and 1 patient in
arm 1 (4%) and none in arm 2maintained PASI 100 (Table 2).
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Figure 2: Median PASI values [25∘–75∘ percentile] at baseline (T0)
and after 12 weeks (T12) in patients treated with topical methylpred-
nisolone + Meriva (curcumin) or with topical methylprednisolone
+ placebo (placebo). ∗𝑃 < 0.05.
Table 2: Efficacy secondary end points at T12 and at T16.
T12 T16
Arm 1 Arm 2 Arm 1 Arm 2
PASI 50 23/25 (92%) 13/24 (54%) 22/25 (88%) 11/24 (46%)
PASI 75 12/25 (48%) 3/24 (12%) 11/25 (44%) 2/24 (8%)
PASI 90 5/25 (20%) 1/24 (4%) 2/25 (8%) 0/24 (0%)
PASI 100 3/25 (12%) 1/24 (4%) 1/25 (4%) 0/24 (0%)
3.2. Safety End Points. Only one out of 31 patients who
received the study product and 2 out of 32 patients receiving
placebo reported one adverse event. The patient treated with
Meriva complained of diarrhoea for two days and decided to
discontinue the study protocol after 8 weeks; diarrhoea was
also associatedwith fever as well as to other symptoms of viral
gastroenteritis; however it was not possible to assess the exact
aetiology neither to attribute the adverse effect to the study
product.
As far as the two patients administeredmatching placebo,
one complained of a papular eruption on the face occurring
after 5 weeks of therapy that was attributed to the study
product by the patient who decided to retire from the trial.
The other one suffered of nausea that occurred after 3 weeks
and persisted for two weeks until the discontinuation of the
therapy.
3.3. Serum Levels of Th17-Related Cytokines. IL-17 and IL-22
were detected in all the patients. At T0, both groups showed
similar IL-17 levels, without significant differences (32.3±13.6
in group 1 and 30.7 ± 12.2 in group 2, resp.; Figure 3). After
the treatment, at T12, no significant changes in IL-17 serum
concentrations can be observed in both groups (30.7 ± 10.9
in group 1 and 28.8 ± 12.9 in group 2, resp.; Figure 3).
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Figure 3: IL-17 and IL-22 mean values ± standard deviation at
baseline (T0) and after 12 weeks (T12) in patients treated with
topical methylprednisolone + Meriva (curcumin) or with topical
methylprednisolone + placebo (placebo). Data are expressed as
pg/mL. ∗𝑃 < 0.05.
As for IL-17, IL-22 levels were similar in the two groups
of patients with psoriasis at T0 (35.2 ± 9.5 in group 1 and
32.9 ± 11 in group 2, resp.; Figure 3). Interestingly, after
12 weeks, patients treated with topical methylprednisolone
aceponate plus Meriva achieved a significant reduction of IL-
22 serum levels (21.1±7.5; IL-22 at T0 versus IL-22 at T12:𝑃 <
0.001), while the treatment with topical methylprednisolone
aceponate plus placebo did not affect IL-22 expression (28.8±
10; Figure 3).
4. Discussion
The primary objective of our study was to investigate the
efficacy of Meriva, a patented bioavailable formulation of
curcumin, as an adjuvant therapy in patients with mild-to-
moderate psoriasis vulgaris (PASI < 10) that are using topical
steroids.
Our data demonstrated that the combination of methyl-
prednisolone aceponate 0.1% ointment plus Meriva was
superior to methylprednisolone aceponate 0.1% ointment
plus placebo in treating psoriasis. In fact, although both
regimens were able to significantly affect psoriasis lesions,
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patients using both topical steroid and Meriva showed a
reduction of PASI values that was significantly higher than
that of patients using topical steroid plus placebo. Moreover,
the group treated with topical steroid and oral bioavailable
curcumin achieved best PASI 50, PASI 75, PASI 90, and
PASI 100 scores than patients treated with topical steroid
plus placebo, suggesting that oral curcuminmight be a useful
adjuvant treatment for patients with psoriasis.
Moreover, oral curcumin was well tolerated in our study.
In fact, only one patient discontinued the therapy due to
adverse effects, namely, diarrhea, which was more likely
associated with a viral gastroenteritis rather than with the
drug itself. Accordingly, other studies confirmed the safety
of curcumin in human beings, even at high doses [14], being
mild gastrointestinal upset the most common complaint.
Our results are partially in contrast with those from
a previous study, where curcumin was used alone for the
treatment of patients with psoriasis [25]. In that study, the
authors tested 4.5 g per day of oral curcuminoid C3 complex
in 12 patients with psoriasis, of which only 8 completed the
treatment protocol, with an intention-to-treat response rate
of 16.7% and an as-treated response rate of 25% (considering
responders the patients that achieved an improvement of
their skin lesions >50%, as assessed by physician global
assessment). However, the limited efficacy of curcumin in
such a study could be related to the low number of patients
enrolled in the trial or to the low bioavailability of the
used oral curcumin formulation, probably secondary to its
extensive reduction and conjugation in the intestinal tract
[35, 36], as stated by the authors.
By contrast, the formulation of curcumin used in our
study through the lipidic matrix can capitalize on the rapid
exchange of phospholipids between biological membranes
and the extracellular fluids, shuttling phenolics into biological
membranes and increasing their cellular absorption.
In fact curcumin, as other dietary phenolics, is sparingly
soluble both in water and in oily solvents but shows polar
groups that can interact with the polar heads of phospholipids
[37].
As a result, curcumin combination with phospholipids
according to the Phytosome technology, as applied inMeriva,
showed a marked increase in the concentration of plasma
curcuminoids after oral administration in healthy volunteers
[38], improving the clinical benefits at dosages significantly
lower than those associated with uncomplexed curcumin.
As previously reported, curcumin can be effective in
treating psoriasis by affecting several pathogenetic pathways.
Moreover, recent studies performed in autoimmune models
suggest that curcumin can modulate T helper immune
responses, downregulating the Th1 and Th17 cell pathways
[39, 40]. Accordingly, such activities might operate even
in psoriasis. In fact, in a mouse model of imiquimod-
induced psoriasis-like inflammation, topical curcumin was
demonstrated to improve the skin lesions with an effect
comparable to that of clobetasol and to significantly decrease
the cutaneous levels of IL-17A, IL-17F, IL-22, IL-1𝛽, IL-6, and
TNF-𝛼mRNA [41].
Interestingly, we observed that only the treatment with
topical methylprednisolone aceponate 0.1% plus Meriva was
able to significantly downregulate the concentrations of IL-
22 in the serum of patients with psoriasis. As it is known,
IL-22 is the prototypic cytokine secreted byTh22 cells, a sub-
population of T cells that selectively produces IL-22, but not
IFN-𝛾 nor IL-17. Several studies demonstrated thatTh22 cells
are increased in patients with psoriasis [28, 29, 42] and that
IL-22 plays a major role in several steps of the pathogenesis
of the disease, including inflammation and the proliferation
of keratinocytes [43]. In fact, IL-22 induces keratinocytes to
produce antimicrobial peptides, S100 acute-phase proteins,
and chemokines (such as IL-8) and chemokine receptors, thus
leading to neutrophilic chemotaxis within psoriasis lesions
[44, 45]. Furthermore, IL-22 strongly induces hyperplasia of
in vitro reconstituted human epidermis [45–47] and may be
responsible for the acanthosis typically found in psoriasis.
As a result, the effect on IL-22 and, therefore, on the Th22
pathway, may be included among the potential antipsoriatic
activities of curcumin.
5. Conclusions
In conclusion, our study demonstrated that Meriva, a novel
lecithin based delivery form of curcumin, can be regarded
as a safe and effective ingredient, useful for the adjuvant
therapy of patients with mild-to-moderate plaque psoriasis
vulgaris treated with topical steroids. Among the several
biological effects of curcumin, the ability to downregulate
T cell-mediated inflammation, and in particular the Th22
pathway, may be considered one of the major mechanisms by
which the product can control psoriasis.
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